dm+d

Unassigned

New Medicines

Proellex-V, ProellexUterine fibroids

Information

Proellex-V, Proellex
New molecular entity
Not Known
Allergan

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Nov 19Not listed in company pipeline; assume development discontinued [9].

Category

Selective progesterone receptor antagonist
At least 1 in 4 women develop one or more fibroids in their lifetime. They usually develop in women aged 30-50. Fibroids are more common in women from Afro-Caribbean origin and in women who weigh over 70 kg (11 stones) (patient.co.uk)
Uterine fibroids
Vaginal

ProellexEndometriosis

Information

Proellex
New molecular entity
Not Known
Allergan

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Nov 19Not listed in company pipeline; assume development discontinued [20].

Category

Selective progesterone receptor antagonist
Endometriosis is estimated to affect 5-10% of women of reproductive age. However, it is difficult to determine the prevalence because of the diversity of symptoms and their severity, and because endometriosis may be asymptomatic. Endometriosis has a much higher prevalence in infertile women, estimated as between 25% and 40% [13].
Endometriosis
Oral